Abstract：Small cell lung cancer (SCLC) is highly malignant, aggressive and prone to brain metastasis. Several guidelines recommend prophylactic cranial irradiation (PCI) as the standard treatment for SCLC patients who have achieved complete remission after initial systemic treatment. However, in the modern era, magnetic resonance imaging (MRI) has been commonly applied in the diagnosis of brain metastasis, while radiotherapy combined with immunotherapy and molecular targeted therapy are widely adopted in the treatment of lung cancer. The value of PCI in SCLC has been questioned and challenged. In addition, the application of hippocampal avoidance and drugs to reduce the damage of neurocognitive function after PCI has also become a research hotspot. In this article, the research progress on PCI was reviewed with the latest literature, aiming to provide reference for selecting the most suitable individualized treatment for patients receiving PCI.
Yan Ke,Shen Wenbin,Zhu Shuchai. Clinical value and research progress on prophylactic cranial irradiation in small cell lung cancer under advanced diagnosis and treatment technology[J]. Chinese Journal of Radiation Oncology, 2022, 31(7): 666-670.
[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. DOI: 10.3322/caac.21590. [2] Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review (CSR) 1975-2016. [EB/OL][2019-11-12]. https://seer.cancer.gov/csr/1975_2016/. [3] Arriagada R, Le Chevalier T, Rivière A, et al.Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients[J]. Ann Oncol, 2002, 13(5):748-754. DOI: 10.1093/annonc/mdf123. [4] Sas-Korczyńska B, Korzeniowski S, Wójcik E.Comparison of the effectiveness of "late" and "early" prophylactic cranial irradiation in patients with limited-stage small cell lung cancer[J]. Strahlenther Onkol, 2010, 186(6):315-319. DOI: 10.1007/s00066-010-2088-3. [5] Manapov F, Käsmann L, Roengvoraphoj O, et al.Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes[J]. Lung Cancer (Auckl), 2018, 9:49-55. DOI: 10.2147/LCTT.S137577. [6] Aupérin A, Arriagada R, Pignon JP, et al.Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group[J]. N Engl J Med, 1999, 341(7):476-484. DOI: 10.1056/NEJM199908123410703. [7] Meert AP, Paesmans M, Berghmans T, et al.Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis[J]. BMC Cancer, 2001, 1:5. DOI: 10.1186/1471-2407-1-5. [8] Seute T, Leffers P, ten Velde GP, et al. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI)[J]. Cancer, 2008, 112(8):1827-1834. DOI: 10.1002/cncr.23361. [9] Yılmaz U, Kırakli EK, Gürlek Ü, et al.Frequency of silent brain metastasis before prophylactic cranial irradiation in small cell lung cancer[J]. Turk Thorac J, 2017, 18(1):11-13. DOI: 10.5152/TurkThoracJ.2017.16022. [10] Ozawa Y, Omae M, Fujii M, et al.Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer[J]. BMC Cancer, 2015, 15:589. DOI: 10.1186/s12885-015-1593-2. [11] Mamesaya N, Wakuda K, Omae K, et al.Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy[J]. Oncotarget, 2018, 9(25):17664-17674. DOI: 10.18632/oncotarget.24830. [12] Pezzi TA, Fang P, Gjyshi O, et al.Rates of overall survival and intracranial control in the magnetic resonance imaging era for patients with limited-stage small cell lung cancer with and without prophylactic cranial irradiation[J]. JAMA Netw Open, 2020, 3(4):e201929. DOI: 10.1001/jamanetworkopen.2020.1929. [13] Koh M, Song SY, Jo JH, et al.The value of prophylactic cranial irradiation in limited-stage small cell lung cancer: should it always be recommended?[J]. Radiat Oncol J, 2019, 37(3):156-165. DOI: 10.3857/roj.2019.00318. [14] De Ruysscher D, Dingemans AC, Praag J, et al.Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell lung cancer: a randomized phase III NVALT-11/DLCRG-02 study[J]. J Clin Oncol, 2018, 36(23):2366-2377. DOI: 10.1200/JCO.2017.77.5817. [15] Sun A, Hu C, Wong SJ, et al.Prophylactic cranial irradiation vs observation in patients with locally advanced non-small cell lung cancer: a long-term update of the NRG oncology/RTOG 0214 phase 3 randomized clinical trial[J]. JAMA Oncol, 2019, 5(6):847-855. DOI: 10.1001/jamaoncol.2018.7220. [16] Hoda MA, Klikovits T, Klepetko W.Controversies in oncology: surgery for small cell lung cancer? It's time to rethink the case[J]. ESMO Open, 2018, 3(3):e000366. DOI: 10.1136/esmoopen-2018-000366. [17] Brock MV, Hooker CM, Syphard JE, et al.Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: its time has come[J]. J Thorac Cardiovasc Surg, 2005, 129(1):64-72. DOI: 10.1016/j.jtcvs.2004.08.022. [18] Yang CJ, Chan DY, Shah SA, et al.Long-term survival after surgery compared with concurrent chemoradiation for node-negative small cell lung cancer[J]. Ann Surg, 2018, 268(6):1105-1112. DOI: 10.1097/SLA.0000000000002287. [19] Bischof M, Debus J, Herfarth K, et al.Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy[J]. Strahlenther Onkol, 2007, 183(12):679-684. DOI: 10.1007/s00066-007-1740-z. [20] Yokouchi H, Ishida T, Yamazaki S, et al.Prognostic impact of clinical variables on surgically resected small-cell lung cancer: results of a retrospective multicenter analysis (FIGHT002A AND HOT1301A)[J]. Lung Cancer, 2015, 90(3):548-553. DOI: 10.1016/j.lungcan.2015.10.010. [21] Lou Y, Zhong R, Xu J, et al.Does surgically resected small-cell lung cancer without lymph node involvement benefit from prophylactic cranial irradiation?[J]. Thorac Cancer, 2020, 11(5):1239-1244. DOI: 10.1111/1759-7714.13381. [22] Xu J, Yang H, Fu X, et al.Prophylactic cranial irradiation for patients with surgically resected small cell lung cancer[J]. J Thorac Oncol, 2017, 12(2):347-353. DOI: 10.1016/j.jtho.2016.09.133. [23] Yang Y, Zhang D, Zhou X, et al.Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis[J]. J Cancer, 2018, 9(2):433-439. DOI: 10.7150/jca.21465. [24] Putora PM, De Ruysscher D, Glatzer M, et al.The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: patient selection among ESTRO experts[J]. Radiother Oncol, 2020, 145:45-48. DOI: 10.1016/j.radonc.2019.11.022. [25] Slotman B, Faivre-Finn C, Kramer G, et al.Prophylactic cranial irradiation in extensive small-cell lung cancer[J]. N Engl J Med, 2007, 357(7):664-672. DOI: 10.1056/NEJMoa071780. [26] Takahashi T, Yamanaka T, Seto T, et al.Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(5):663-671. DOI: 10.1016/S1470-2045(17)30230-9. [27] Nosaki K, Seto T, Shimokawa M, et al.Is prophylactic cranial irradiation (PCI) needed in patients with extensive-stage small cell lung cancer showing complete response to first-line chemotherapy?[J]. Radiother Oncol, 2018, 127(3):344-348. DOI: 10.1016/j.radonc.2018.04.010. [28] Slotman BJ.Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer?[J]. Lancet Oncol, 2017, 18(5):566-567. DOI: 10.1016/S1470-2045(17)30193-6. [29] Sharma S, McMillan M, Doucette A, et al. Impact of prophylactic cranial irradiation on overall survival in metastatic small cell lung cancer: a propensity score matched analysis of patients in the National Cancer Database[J].Int J Radiat Oncol Biol Phys, 2017,98(1):224-225. DOI:10.1016/j.ijrobp.2017.01.064. [30] Bang A, Kendal WS, Laurie SA, et al.Prophylactic cranial irradiation in extensive stage small cell lung cancer: outcomes at a comprehensive cancer centre[J]. Int J Radiat Oncol Biol Phys, 2018, 101(5):1133-1140. DOI: 10.1016/j.ijrobp.2018. 04.058. [31] National Comprehensive Cancer Network. NCCN Guidelines, SCLC, version 3.2020.[S/OL][2020-08-15]. https://www.nccn.org/. Accessed: February 5,2020. [32] Gondi V, Paulus R, Bruner DW, et al.Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of radiation therapy oncology group randomized trials 0212 and 0214[J]. Int J Radiat Oncol Biol Phys, 2013, 86(4):656-664. DOI: 10.1016/j.ijrobp.2013.02.033. [33] Wolfson AH, Bae K, Komaki R, et al.Primary analysis of a phase II randomized trial radiation therapy oncology group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(1):77-84. DOI: 10.1016/j.ijrobp.2010.05.013. [34] Gondi V, Hermann BP, Mehta MP, et al.Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors[J]. Int J Radiat Oncol Biol Phys, 2013, 85(2):348-354. DOI: 10.1016/j.ijrobp.2012.11.031. [35] Ma TM, Grimm J, McIntyre R, et al. A prospective evaluation of hippocampal radiation dose volume effects and memory deficits following cranial irradiation[J]. Radiother Oncol, 2017, 125(2):234-240. DOI: 10.1016/j.radonc.2017.09.035. [36] Harth S, Abo-Madyan Y, Zheng L, et al.Estimation of intracranial failure risk following hippocampal-sparing whole brain radiotherapy[J]. Radiother Oncol, 2013, 109(1):152-158. DOI: 10.1016/j.radonc.2013.09.009. [37] Marsh JC, Herskovic AM, Gielda BT, et al.Intracranial metastatic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patients[J]. Int J Radiat Oncol Biol Phys, 2010, 76(2):504-512. DOI: 10.1016/j.ijrobp.2009.02.038. [38] Redmond KJ, Hales RK, Anderson-Keightly H, et al.Prospective study of hippocampal-sparing prophylactic cranial irradiation in limited-stage small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 98(3):603-611. DOI: 10.1016/j.ijrobp.2017.03.009. [39] Kundapur V, Ellchuk T, Ahmed S, et al.Risk of hippocampal metastases in small cell lung cancer patients at presentation and after cranial irradiation: a safety profile study for hippocampal sparing during prophylactic or therapeutic cranial irradiation[J]. Int J Radiat Oncol Biol Phys, 2015, 91(4):781-786. DOI: 10.1016/j.ijrobp.2014.12.026. [40] Gondi V, Pugh SL, Tome WA, et al.Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial[J]. J Clin Oncol, 2014, 32(34):3810-3816. DOI: 10.1200/JCO.2014.57.2909. [41] 董昕, 周宗玫, 刘璇, 等. 小细胞肺癌全脑预防照射海马回区保护的Ⅱ期临床研究[J]. 中华放射肿瘤学杂志, 2018, 27(7): 638-642. DOI: 10.3760/cma.j.issn.1004-4221.2018.07.003. Dong X, Zhou ZM, Liu X, et al.Phase Ⅱ clinical trial of hippocampal-sparing prophylactic cranial irradiation in patients with small cell lung cancer[J]. Chin J Radiat Oncol,2018,27(7):638-642. DOI: 10.3760/cma.j.issn.1004- 4221.2018.07.003. [42] Rodríguez de Dios N, Couñago F, López JL, et al. Treatment design and rationale for a randomized trial of prophylactic cranial irradiation with or without hippocampal avoidance for SCLC: PREMER trial on behalf of the oncologic group for the study of lung cancer/spanish radiation oncology group-radiation oncology clinical research group[J]. Clin Lung Cancer, 2018, 19(5):e693-e697. DOI: 10.1016/j.cllc.2018. 05.003. [43] Brown PD, Pugh S, Laack NN, et al.Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial[J]. Neuro Oncol, 2013, 15(10):1429-1437. DOI: 10.1093/neuonc/not114. [44] Horn L, Mansfield AS, Szczęsna A, et al.First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. [45] Paz-Ares L, Dvorkin M, Chen Y, et al.Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6.
2022, Vol. 31 
